- 期刊
- OpenAccess
Lack of Correlation of Continuous Performance Test with Plasma Levels of Haloperidol in Patients with Schizophrenia
Haloperidol血中濃度與注意力無相關
摘要
目的：過去文獻發現高劑量典型抗精神病藥物可能會影響選擇性或持續性注意力然為定論。本研究為探討haloperidol血中濃度與持續性注意力continuous performance test(CPT)之間的關係。方法：於台灣某二家綜合醫院選取四位男性、四位女性符合DSM-IV診斷之精神分裂症且使用haloperidol滿一年以上之患者，以液相層析法併用質譜(LC/MS/MS)量測病人在執行CPT測驗同一天清晨血中的haloperidol濃度。結果：haloperidol血中濃度與CPT之間沒有達到統計上的顯著性。結論：haloperidol血中濃度與持續性注意力之間可能沒有相關性。
並列摘要
Objective: The relationship between high dosages of antipsychotic and the development of cognitive deficits requires further investigation. The aim of this study was to examine the correlation between Continuous Performance Test (CPT) and plasma level of haloperidol in patients with schizophrenia. Methods: Eight patients with schizophrenia, including four males and four females, who had been taking haloperidol for more than one year were enrolled. Subject responses were recorded automatically using the CPT machine on the day of blood sampling. The plasma concentration of haloperidol was determined by liquid chromatography-tandem mass spectrometry (LC/MS/MS). Results: No correlation was found between the CPT results and plasma levels of haloperidol. Conclusion: CPT score might be a stable vulnerability indicator for schizophrenia. The plasma level of haloperidol may not affect CPT performance directly.